Rhinosinusitis Clinical Trial
Official title:
Open-label Comparative Safety and Efficacy Study of Levofloxacin and Amoxicillin Clavulanic Acid in Patients With Acute ,Bacterial Rhinosinusitis
Inflammatory paranasal diseases are among the most common diseases in ENT In Russia,
puncture method has been conventional approach to treatment of maxillary sinusitis. However,
this procedure is associated with a number of drawbacks A promising trend for the treatment
of purulent sinusitis is a reasonable antibacterial therapy Fluoroquinolones, particularly
levofloxacin, are highly active against pneumonocci and are more active vs. the drug
products of the second generation against intracellular agents (Chlamydia spp., Mycoplasma
spp., M. tuberculosis, rapidly growing atypical mycobacteria (M. avium, etc.).
Due to high activity against the agents causing bacterial upper and lower respiratory tract
infections they are sometimes called "respiratory" fluoroquinolones
Inflammatory diseases of paranasal sinuses occupy one of the leading positions in the
overall structure of ENT-diseases.
Puncture method has been a conventional approach to the treatment of suppurative maxillary
sinusitis in Russia until present. However, this relatively simple and conventional
treatment method has a number of disadvantages. Fear of an unpleasant procedure is
justified. Generally, single puncture does not ensure healing, and the doctor has to install
drainage or of perform repeated manipulations significantly reducing quality of life during
the disease period. There is also a certain risk of puncture needle penetration into
adjacent areas. Sometimes direct contraindications to punctures exist (intolerance of
topical anesthetics, blood clotting disorders, etc.).
The puncture itself, as an independent method, is a relieving procedure rather than a
pathognomonic treatment method, especially regarding severe combined forms of sinusitis with
risk of intracranial complications. Due to lacking standardized antibacterial drugs to be
injected into the sinus, multiple punctures are erroneously considered to be able of
eliminating the bacterial agent successfully.
One of the promising trends regarding the treatment of suppurative maxillary sinusitis is an
adequate antibacterial therapy. Fluoroquinolones of last generations, levofloxacin in
particular, which are highly active against pneumococci, are more effective vs. generation
II drugs against intracellular agents (Chlamydia spp., Mycoplasma spp., M.tuberculosis,
rapidly growing atypical mycobacteria (M.avium, etc.). At that activity towards other
gram-negative bacteria is not reduced. An important property of these drugs consists in
activity regarding a number of bacteria resistant to generation II fluoroquinolones. Due to
high activity against the agents of upper and lower respiratory bacterial infections they
are sometimes called "respiratory" fluoroquinolones.
According to a publication, Levofloxacin 500 mg q.d. for 5 days eliminated radiological
signs of the disease by the end of the course in 65% subjects, while 35% showed positive
changes only (М.А. Panyakina, 2012). Based on these findings, otolaryngologists have to
obtain higher therapeutic efficacy levels with the same 5-day course, since this treatment
term demonstrates violated compliance most frequently. One of the options is an elevation of
daily dose. In particular, Rameez Shah (2013) published data concerning high efficacy of
levofloxacin at a daily dose of 750 mg for 5 days.
Necessity to search ways to shorten the current course of antibiotic therapy is being under
discussion at all levels. Particularly, 24th European Congress of Clinical Microbiology and
Infectious Diseases performed on May 10-13, 2014 in Barcelona (ECCMID 2014) repeatedly
raised question concerning revision of the current treatment standards and clinical
recommendations concerning duration of antibiotic therapy and dosing regimens.
Based on the above-mentioned findings, it would be interesting to evaluate efficacy of
various antibiotic schemes (respiratory fluoroquinolones or protected aminopenicillin) in
hospital conditions.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02636790 -
Early Versus Late Surgical Wait Times
|
Early Phase 1 | |
Completed |
NCT00986830 -
Healthcare Utilization and Outcomes of FinESS Treatment in the Office
|
N/A | |
Completed |
NCT00534079 -
Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
|
Phase 3 | |
Completed |
NCT05442606 -
Physiotherapy Protocol in Treating Chronic Rhinosinusitis
|
N/A | |
Completed |
NCT01955980 -
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis
|
Phase 1/Phase 2 | |
Completed |
NCT04123405 -
Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis
|
Phase 3 | |
Completed |
NCT00797004 -
Olfactory Dysfunction of Rhinosinusitis
|
N/A | |
Recruiting |
NCT05494346 -
Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction
|
N/A | |
Not yet recruiting |
NCT05836935 -
Role of Imaging in Complications of Sinusitis
|
N/A | |
Withdrawn |
NCT02097576 -
Manuka Honey Nasal Rinse Study
|
N/A | |
Completed |
NCT01132781 -
Theophylline in Rhinitis
|
Phase 2 | |
Recruiting |
NCT00948519 -
Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents
|
N/A | |
Completed |
NCT00554190 -
Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel
|
Phase 4 | |
Recruiting |
NCT03729258 -
Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis.
|
Phase 3 | |
Withdrawn |
NCT03729310 -
Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis
|
Early Phase 1 | |
Recruiting |
NCT01296919 -
The Clinical Significance of the Uncinate Process Histopathology in Chronic Rhinosinusitis
|
N/A | |
Completed |
NCT01086839 -
Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
|
N/A | |
Completed |
NCT00849953 -
FinESS Registry Study
|
N/A | |
Withdrawn |
NCT00669799 -
Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study
|
N/A | |
Completed |
NCT03229551 -
Xylitol for Chronic Sinusitis
|
Phase 2/Phase 3 |